Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 5. MMP-7 expression in human liver, EHBD, and gallbladder.

Published byΠαρθενιά Βουρδουμπάς Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 5. MMP-7 expression in human liver, EHBD, and gallbladder."— Presentation transcript:

1 Fig. 5. MMP-7 expression in human liver, EHBD, and gallbladder.
MMP-7 expression in human liver, EHBD, and gallbladder. (A) Immunohistochemical staining of normal human liver shows minimal or no expression of MMP-7 in hepatocytes and IHBDs but intense expression in the biliary epithelium of gallbladder (GB) and EHBD. Scale bars, 50 μm (in liver, GB, and EHBD) and 20 μm (in IHBD). (B) Variable intensity of expression (0 to 3+) of MMP-7 in the cytoplasm of intrahepatic biliary epithelium of BA subjects. (C) Livers of patients with α1-antitrypsin deficiency had lower MMP-7 expression in the IHBDs. Scale bar, 20 μm for both (B) and (C). (D) Percentage of livers showing different intensities of MMP-7 immunostaining in patients with BA and α1-antitrypsin (A1AT) deficiency. (E) Hepatic mRNA expression of MMP-7 for BA (n = 64), IHC (n = 14), and NC (n = 7). Expression is normalized to NCs and presented as fold change. P values are from Kruskal-Wallis test. Chatmanee Lertudomphonwanit et al., Sci Transl Med 2017;9:eaan8462 Published by AAAS

Download ppt "Fig. 5. MMP-7 expression in human liver, EHBD, and gallbladder."

Similar presentations

Fig. 1. TP is highly expressed in myeloma.

Fig. 1. TP is highly expressed in myeloma.
Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.

Fig. 1. Potent and selective down-regulation of KRAS mRNA and protein by AZD4785 in vitro and in vivo. Potent and selective down-regulation of KRAS mRNA.
Fig. 5. Blocking LTB4 during initial lymphangiogenesis period abrogates the therapeutic benefit of LTB4 antagonism. Blocking LTB4 during initial lymphangiogenesis.

Fig. 5. Blocking LTB4 during initial lymphangiogenesis period abrogates the therapeutic benefit of LTB4 antagonism. Blocking LTB4 during initial lymphangiogenesis.
Fig. 4. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin expression. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin.

Fig. 4. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin expression. Intramuscular injection of AAV9-Cas9/sgRNA-51 corrects dystrophin.
Fig. 8. Gene and protein changes in ALK-dependent STING pathways in human sepsis. Gene and protein changes in ALK-dependent STING pathways in human sepsis.

Fig. 8. Gene and protein changes in ALK-dependent STING pathways in human sepsis. Gene and protein changes in ALK-dependent STING pathways in human sepsis.
Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.

Fig. 5. Correlation of tail and long bone growth velocities with Cxm serum concentrations in mice. Correlation of tail and long bone growth velocities.
Fig. 4. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive and HBeAg-negative chimpanzees. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive.

Fig. 4. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive and HBeAg-negative chimpanzees. Liver HBV mRNA paired-end sequencing reads in HBeAg-positive.
Fig. 3. Obese IFN-γ−/− mice develop accelerated NAFLD with fibrosis.

Fig. 3. Obese IFN-γ−/− mice develop accelerated NAFLD with fibrosis.
Fig. 1. Schematic representation of the MANO method.

Fig. 1. Schematic representation of the MANO method.
Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells.

Fig. 1 Localized treatment of TNBC cancers kills tumor cells and minimizes the metastatic burden. Localized treatment of TNBC cancers kills tumor cells.
Fig. 6. N95BA5 biocompatibility beyond intended use frame.

Fig. 6. N95BA5 biocompatibility beyond intended use frame.
Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.

Fig. 6 Bimodal treatment results in reduced tinnitus loudness and reduced TFI scores in human patients. Bimodal treatment results in reduced tinnitus loudness.
Fig. 3. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with ARC-520. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with.

Fig. 3. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with ARC-520. Serum HBsAg and liver HBV mRNA reduction in chimpanzees dosed with.
Fig. 1. NASH and fibrosis develop late in mice fed an HFD.

Fig. 1. NASH and fibrosis develop late in mice fed an HFD.
Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.

Fig. 8. mRIPO elicits neutrophil influx followed by DC and T cell infiltration into tumors. mRIPO elicits neutrophil influx followed by DC and T cell infiltration.
Fig. 4. Characterization of human liver seed graft morphology.

Fig. 4. Characterization of human liver seed graft morphology.
Fig. 2. GPC3 expression in normal and tumor tissues.

Fig. 2. GPC3 expression in normal and tumor tissues.
Fig. 5. Immunohistochemistry of the tumor microenvironment in GBM specimens before and after CART-EGFRvIII infusion. Immunohistochemistry of the tumor.

Fig. 5. Immunohistochemistry of the tumor microenvironment in GBM specimens before and after CART-EGFRvIII infusion. Immunohistochemistry of the tumor.
Expression of CD36 and psap in a TMA of human ovarian cancer patients

Expression of CD36 and psap in a TMA of human ovarian cancer patients
Increased ADMA in pregnancy is associated with SGA birth outcomes

Increased ADMA in pregnancy is associated with SGA birth outcomes

Similar presentations

Ads by Google